Revolo Biotherapeutics

Focus: Revolo Biotherapeutics is a newly founded (2024) UK-based biotech focused on therapies for inflammatory and immunological diseases, currently in early-stage clinical development with no approved products.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Revolo Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Revolo Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IRL201104

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT05921591Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Phase 1

Help build intelligence for Revolo Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public company (2024) with potential for rapid equity value creation if clinical programs succeed
Focused immunology and inflammation pipeline allows deep specialization in high-unmet-need therapeutic areas
Early-stage company structure enables broader cross-functional exposure and faster individual impact than large pharma

Watch Out For

Zero current job openings (activeJobCount: 0) signals either very early hiring stage or limited near-term expansion
No approved products, no revenue, and no disclosed funding/cash position create financial runway uncertainty
Extremely early clinical stage (only Phase 2 programs, no Phase 3) means 5–10+ years to potential value inflection

Generated by Claude from Revolo Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

IRL201104

Healthy Volunteer

PHASE_1

Clinical Trials (1)

NCT04748536Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Phase 1

IRL201104

Seasonal Allergic Rhinitis

PHASE_2

Clinical Trials (1)

NCT05098522Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Phase 2

IRL201104

Eosinophilic Esophagitis

PHASE_2

Clinical Trials (1)

NCT05084963A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 4 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo